Next 10 |
2024-04-16 12:22:50 ET More on rare disease pharmas/biotechs Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success...
2024-04-15 09:42:46 ET Shares of Ultragenyx Pharmaceutical ( NASDAQ: RARE ) plunged as much as 7% on Monday after the company reported serious adverse effects in a gene therapy trial evaluating its investigational drug candidate, GTX-102, in patients with Angelman syndrome.... ...
Expansion Cohorts showed rapid, clinically meaningful improvement across multiple domains; improvements consistent or exceeding Dose-escalation Cohorts data at Day 170 Additional long-term data in Dose-escalation Cohorts showed increasing and sustained clinical benefit through Day 758 Com...
Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link below NOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the conference call to discuss new clinical efficacy and safety ...
NOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that preclinical and clinical data, including new clinical efficacy and safety data from the expansion cohorts in the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome,...
2024-03-28 13:46:05 ET More on Invesco S&P 500 Equal Weight ETF: RSP: Equal Weighting The S&P 500 To Minimize Magnificent Seven Exposure Is Not Optimal RSP: I Firmly Believe In An Allocation To Equal-Weight At This Juncture RSP: Happy 2024! Don't Make Decisio...
2024-03-18 11:30:02 ET Wedbush analyst issues BUY recommendation for RARE on March 18, 2024 09:00AM ET. The previous analyst recommendation was Buy. RARE was trading at $47.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
2024-03-11 11:53:40 ET Summary Positive interim results released from phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. Functional and strength data from the phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients...
2024-03-09 09:55:42 ET Summary Ultragenyx's stock has increased by approximately 9% but lags behind the S&P's return of 28%. The article assesses Ultragenyx's current merits per its recently reported Q4, 2023 earnings as we progress into 2024. The previous "Sell" rating ba...
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 whi...
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the P...
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,11...